| Ytd | 269.30% | |
| 1y | 167.58% |
| Open | 12.56 | Prev Close | 12.73 | Low | 12.37 | High | 12.96 | Mkt Cap | 4.09B |
| Vol | 5.44M | Avg Vol | 7.49M | EPS | -0.54 | P/E | N/A | Forward P/E | -17.66 |
| Beta | 1.32 | Short Ratio | 3.49 | Inst. Own | 36.69% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 9.00 | 200-d Avg | 5.45 | 1yr Est | 17.13 |
AbCellera (NASDAQ:ABCL) today announced an upcoming oral presentation of Phase 2 data on ABCL635 at
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation of Phase 2
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Cantor Global He
BlackRock Inc. purchased a new position in shares of AbCellera Biologics Inc. (NASDAQ: ABCL) during
AbCellera Biologics Inc. (NASDAQ:ABCL) stock is trading higher on Tuesday. Year-to-date, the stock h
AbCellera Biologics stock gains as investors react to Jazz Pharmaceuticals’ FDA approval and the com
Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million.
Biotech, especially small-cap names, is experiencing renewed optimism as macro and policy headwinds
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Pricing of Oversubscribe
AbCellera Biologics Inc. (NASDAQ:ABCL) shares are trading higher on Wednesday following the announce
AbCellera shares rise after positive ABCL635 Phase 2 results, while bullish momentum and analyst pri
U.S. stock futures higher, Nasdaq 100 up 150 pts. National CineMedia shares down 16.4% on weak Q2 re
AbCellera Biologics Inc. (NASDAQ:ABCL) ("AbCellera") today announced that it has commenced a
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Proposed Public Offering
Truist Securities analyst Robyn Kamaus maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and
AbCellera Biologics Inc. (NASDAQ: ABCL - Get Free Report) was the target of unusually large options
AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Mode
AbCellera Biologics Inc. (NASDAQ:ABCL) announced positive top-line Phase 2 results from its Phase 1/
AbCellera reports positive Phase 2 clinical trial results for ABCL635, a single-dose treatment for m
Gainers Jin Medical International (NASDAQ:ZJYL) shares rose 58.1% to $3.4 during Monday's regul
AbCellera (ABCL), a Vancouver clinical-stage antibody biotech, rose 33.19% intraday after its experi
BWMN gained 55.1%, HZO rose 45.8%, ABCL gained 35.6%, SLN rose 34.3%, ACHR gained 19.5%, NESR gained
AbCellera Biologics NASDAQ: ABCL reported top-line four-week results from a Phase II trial of ABCL-6
Gainers Jin Medical International (NASDAQ:ZJYL) stock rose 70.7% to $3.67 during Monday's pre-m
[url="]AbCellera[/url] (Nasdaq: ABCL) today announced positive top-line results from the Phase 2 por
Phase 2 results showed best-in-class reductions in both frequency and severity of moderate-to-severe
BKYI: -8% | BIO-key And Visualforma Win Contract To Strengthen Digital Identity Security For Portugu
AbCellera said Monday its experimental menopause treatment significantly reduced the frequency and
Phase 2 results showed best-in-class reductions in both frequency and severity of moderate-to-severe
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Positive Top-Line Phase
Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's afte
Management to host a conference call and live webcast at 4:30 a.m. PT / 7:30 a.m. ETAbCellera (NASDA
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Announce Top-Line Results from
Stifel analyst Stephen Willey maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises t
Cantor Fitzgerald analyst Steve Seedhouse maintains AbCellera Biologics (NASDAQ:ABCL) with a Over
AbCellera Biologics Inc. (ABCL) Q2 2026 Earnings Call Transcript
AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.18 per share versus the Zacks C
AbCellera Biologics NASDAQ: ABCL said it expects to report top-line data “very soon” from its Phase
AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.18) per share which missed the an
Benchmark analyst Robert Wasserman upgrades AbCellera Biologics (NASDAQ:ABCL) from Hold to Buy an
Jazz Pharmaceuticals teams with AbCellera on cancer therapies as analysts maintain positive targets
The collaboration includes $56 million in upfront payments to AbCellera and up to $792 million in po
Risk-off sentiment dominated Wall Street on Friday, with selling pressure in AI-linked names intensi
After a brief and cautious rebound on Wednesday, risk-off sentiment returned sharply on Thursday, wi
U.S. stock futures were fluctuating on Thursday following Wednesday's record advances. Futures o